Janney Montgomery Scott LLC Lowers Stake in Stryker Corporation $SYK

Janney Montgomery Scott LLC lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 17.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 80,254 shares of the medical technology company’s stock after selling 17,151 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Stryker were worth $25,267,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Godfrey Financial Associates Inc. bought a new stake in Stryker during the fourth quarter valued at about $26,000. Sankala Group LLC purchased a new position in Stryker in the fourth quarter valued at about $26,000. United Financial Planning Group LLC bought a new position in Stryker in the third quarter worth about $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker during the fourth quarter valued at about $27,000. Finally, DJE Kapital AG purchased a new stake in shares of Stryker during the fourth quarter valued at about $28,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Price Performance

Shares of SYK stock opened at $338.80 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The firm has a market capitalization of $129.95 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock’s 50-day simple moving average is $324.61 and its 200-day simple moving average is $333.57.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SYK. Wells Fargo & Company cut their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Royal Bank Of Canada cut their price target on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Finally, Robert W. Baird set a $385.00 price target on Stryker in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.